Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson's Disease and L-DOPA-Induced Dyskinesia.

Key Findings:  Researchers present clinical and preclinical evidence suggesting CBD and other cannabinoids have therapeutic effects in Parkinson's disease and L-DOPA-induced dyskinesia.

Type of Study:  Meta-analysis

Study Result:  Positive

Cannabinoids Studied:  Cannabidiol (CBD), Cannabinoid (unspecified), Synthetic Cannabinoid (unspecified)

Phytocannabinoid Source:  Not Applicable

Form of Administration:  Not Applicable

Receptors Studied:  TRPs, PPARs

Ligands Studied:  Anti-inflammatory cytokines, Pro-inflammatory cytokines

Study Location(s):  Brazil

Year of Pub:  2019

Link to study